Resources from the same session
402O - A randomized phase III trial of site-specific therapy guided by the 90-gene expression assay versus empiric chemotherapy in patients with cancer of unknown primary
Presenter: Xin Liu
Session: Mixed Proffered paper and Mini oral session: Developmental and precision medicine
Resources:
Abstract
Slides
Webcast
Q&A and discussion
Presenter: All Speakers
Session: Mixed Proffered paper and Mini oral session: Developmental and precision medicine
Resources:
Webcast
404MO - Tertiary lymphoid structures localization and maturation heterogeneities correlate with divergent microenvironment features and immune responses of clear cell renal cell carcinoma
Presenter: Wenhao Xu
Session: Mixed Proffered paper and Mini oral session: Developmental and precision medicine
Resources:
Abstract
Slides
Webcast
405MO - Pan-cancer analysis of 4-1BB transcriptome expression and its impact on outcome in patients treated with immune checkpoint inhibitors
Presenter: Yuji Uehara
Session: Mixed Proffered paper and Mini oral session: Developmental and precision medicine
Resources:
Abstract
Slides
Webcast
Invited Discussant 404MO and 405MO
Presenter: Aaron Hansen
Session: Mixed Proffered paper and Mini oral session: Developmental and precision medicine
Resources:
Slides
Webcast
Q&A and discussion
Presenter: All Speakers
Session: Mixed Proffered paper and Mini oral session: Developmental and precision medicine
Resources:
Webcast
74MO - Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: Primary analysis from the DESTINY-PanTumor02 (DP-02) study
Presenter: Do-Youn Oh
Session: Mixed Proffered paper and Mini oral session: Developmental and precision medicine
Resources:
Abstract
Slides
Webcast
75MO - Phase I trial of the DLL3/CD3 IgG-like T cell engager BI 764532 in patients (pts) with DLL3+ tumors: Focus on Asian pts
Presenter: Yasutoshi Kuboki
Session: Mixed Proffered paper and Mini oral session: Developmental and precision medicine
Resources:
Abstract
Slides
Webcast
76MO - Efficacy and safety findings from MANTRA: A global, randomized, multicenter, phase III study of the MDM2 inhibitor milademetan vs trabectedin in patients with dedifferentiated liposarcomas
Presenter: Tom Wei-Wu Chen
Session: Mixed Proffered paper and Mini oral session: Developmental and precision medicine
Resources:
Abstract
Slides
Webcast
77MO - A first-in-human, open-label, dose-escalation study of ERK1/2 inhibitor HMPL-295 in patients with advanced solid tumors
Presenter: Rujiao Liu
Session: Mixed Proffered paper and Mini oral session: Developmental and precision medicine
Resources:
Abstract
Slides
Webcast